Literature DB >> 16379620

Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates.

Mark DeLong1, Jim Wright, Mat Dawson, Thomas Meyer, Knut Sommerer, Craig Dunbar.   

Abstract

The purpose of this study was to evaluate the in vitro and in vivo dose delivery characteristics of the AIR pulmonary delivery system over a range of flow rates. A 5-mg placebo powder of engineered particles with low densities (<0.4 g/cc) and large geometric diameters (>5 microm) was delivered via a simple, capsule based, passive dry powder inhaler. The emitted dose, geometric and aerodynamic particle size distributions (aPSDs) were obtained over a range of flow rates (15-60 LPM). The in vitro results demonstrated improved powder dispersion with increasing flow rate through the inhaler. The in vivo dose delivery characteristics were obtained by gamma scintigraphy. Twelve healthy subjects performed the following three inhalation maneuvers: (i) a targeted peak inspiratory flow rate (PIFR) of 20 +/- 10 LPM, (ii) a deep comfortable inhalation, and (iii) a deep forced inhalation. PIFR and inhaled volume were obtained during the inhalation of the dose using a spirometer. In vivo dose delivery was characterized by high and reproducible emitted doses (mean = 87%; inter and intra-subject CV = 5%) and high lung deposition (mean = 51% of the total dose), with low inter and intra-subject CVs (18% and 13%, respectively) across a range of PIFRs (12-86 LPM). Lung deposition of the total dose was shown not to be dependent on PIFR by analysis of variance across the range of inspiratory flow rates (p = 0.29). This was due to the competing effects of smaller aPSDs, increased extrathoracic deposition and higher emitted doses with increasing PIFR. Fully characterizing the effect of inspiratory flow rate requires analysis of the therapeutic response, as well as in vitro dose delivery and lung deposition.

Mesh:

Substances:

Year:  2005        PMID: 16379620     DOI: 10.1089/jam.2005.18.452

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  8 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 2.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

Review 3.  Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Glenardi Glenardi; Tutwuri Handayani; Jimmy Barus; Ghea Mangkuliguna
Journal:  Neurol Clin Pract       Date:  2022-04

Review 4.  Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.

Authors:  Sachin Gharse; Jennifer Fiegel
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

Review 6.  The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.

Authors:  Andrew R Clark; Jeffry G Weers; Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-10-31       Impact factor: 2.849

Review 7.  Inhaled insulin for controlling blood glucose in patients with diabetes.

Authors:  Bernard L Silverman; Christopher J Barnes; Barbara N Campaigne; Douglas B Muchmore
Journal:  Vasc Health Risk Manag       Date:  2007

8.  Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

Authors:  Peter A LeWitt; Rajesh Pahwa; Alexander Sedkov; Ann Corbin; Richard Batycky; Harald Murck
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-11-21       Impact factor: 2.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.